BeiGene Ltd.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 300
- Registration Number
- NCT06742996
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Conditions
- Interventions
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 56
- Registration Number
- NCT06697184
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 93
- Registration Number
- NCT06685718
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 87
- Registration Number
- NCT06637501
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳The First Peoples Hospital of Changzhou, Changzhou, Jiangsu, China
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 170
- Registration Number
- NCT06634589
- Locations
- 🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸University of Michigan Health System, Ann Arbor, Michigan, United States
A First-in-Human Study of BG-C137, an Anti-FGFR2b Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 68
- Registration Number
- NCT06625593
- Locations
- 🇺🇸
Md Anderson Cancer Center, Houston, Texas, United States
🇦🇺Liverpool Hospital, Liverpool, New South Wales, Australia
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
A Study of BG-C477 in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 21
- Registration Number
- NCT06596473
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Yale University, Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸The University of Kansas Cancer Center, Westwood, Kansas, United States
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 87
- Registration Number
- NCT06598800
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸The University of Texas Md Anderson Cancer Center, Houston, Texas, United States
🇺🇸Next Virginia, Fairfax, Virginia, United States
An Investigational Study of BGB-58067 in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 92
- Registration Number
- NCT06589596
- Locations
- 🇦🇺
Linear Clinical Research, Nedlands, Western Australia, Australia
🇺🇸Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California, United States
🇺🇸Adventhealth, Celebration, Florida, United States
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
- Conditions
- Interventions
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 177
- Registration Number
- NCT06585488
- Locations
- 🇺🇸
Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California, United States
🇺🇸University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States
🇺🇸Sidney Kimmel Comprehensive Cancer At Johns Hopkins, Baltimore, Maryland, United States